The pharmaceutical industry takes a serious economic hit after states legalize cannabis, with an average market loss of nearly $10 billion for drugmakers per each legalization event, according to a first-of-its-kind study.
The peer-reviewed research article, published in the journal PLOS ONE on Wednesday, looked at stock return and prescription drug sales data for 556 pharmaceutical companies from 1996 to 2019, analyzing market trends before and after the enactment of medical and adult-use cannabis legalization laws at the state level.
The stock returns were “1.5-2 percent lower at 10 days after legalization,” the study authors found. “Returns decreased in response to both medical and adult-use legalization, for both generic and brand drugmakers. Investors anticipate a single legalization event to reduce drugmaker annual sales by $3 billion on average.”
There are plenty of anecdotal reports, data-based studies, and observational analyses that have signaled that some people use cannabis as an alternative to traditional pharmaceutical drugs like opioid-based painkillers and sleep medications.
To read the complete article, go to www.marijuanamoment.net